Trident Lifeline Ltd
Trident Lifeline Q1 FY27 investor presentation: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Trident Lifeline Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.
The short version
Quarter Revenue (Consolidated): - Q1 FY26: ₹23.6 crores - Q1 FY27: ₹33.7 crores - YoY change: +43% - Quarter Revenue (Standalone): - Q1 FY26: ₹18.8 crores - Q1 FY27: ₹26.8 crores - YoY change: +43% - Volume-specific figures or sales volumes are not explicitly detailed in the quarterly data. - Explicit outlook: - Management commentary mentions confidence in tripling consolidated business over next three years through disciplined execution and operational excellence (Page 5). Q1 FY27 EBITDA: ₹8.5 crores, up 65% YoY from ₹5.2 crores in Q1 FY26 - Q1 FY27 EBITDA margin: 25.3%, improvement of 334 basis points YoY from 21.9% in Q1 FY26 - Q1 FY27 Profit After Tax (PAT): ₹5.1
From Trident Lifeline Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Quarter Revenue (Consolidated):
- Q1 FY26: ₹23.6 crores
- Q1 FY27: ₹33.7 crores
- YoY change: +43%
- Quarter Revenue (Standalone):
- Q1 FY26: ₹18.8 crores
- Q1 FY27: ₹26.8 crores
- YoY change: +43%
- Volume-specific figures or sales volumes are not explicitly detailed in the quarterly data.
- Explicit outlook:
2 more points from Trident Lifeline Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Trident Lifeline Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Trident Lifeline Limited is investing in registrations, market access, sales infrastructure, and manufacturing to drive multi-year revenue growth and margin expansion (Page 26).
- Integrated Manufacturing strategy with a "brownfield expansion" approach to support capacity growth (Page 26, 20).
- TLL Parenterals Limited (injectables manufacturing arm) has operations yet to commence; revenue contribution expected from FY27 onwards with a peak revenue potential of ₹200 crores and 90% utilization (Page 13).
- TNS Pharma Private Limited (pharmaceutical tablets, capsules manufacturing) driving capacity expansion and margin enhancement, reporting FY26 revenue ₹6 crores; peak revenue ₹40 crores, peak utilization 80% (Page 11).
- TLL Elements Limited (cosmetics manufacturing) introduced product portfolio in FY26; peak revenue ₹20 crores and 80% utilization expected at steady state (Page 15).
- TLL Wellness Limited developing herbal and nutraceutical products, with revenue expected to start in FY27 (Page 14).
2 more points from Trident Lifeline Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Trident Lifeline Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Trident Lifeline Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Wanbury Ltd (Q1 FY27)
Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Symbiotec Pharma (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
- Jubilant Pharmova Ltd (Q1 FY27)
2,229 Cr., up 17% YoY (Page 97) . Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key concall takeaways from Beta Drugs Ltd's Q1 FY27…
Arthneeti Pro · Annual
Trident Lifeline Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Trident Lifeline Ltd Q1 FY27 results?
Quarter Revenue (Consolidated): - Q1 FY26: ₹23.6 crores - Q1 FY27: ₹33.7 crores - YoY change: +43% - Quarter Revenue (Standalone): - Q1 FY26: ₹18.8 crores - Q1 FY27: ₹26.8 crores - YoY change: +43% - Volume-specific figures or sales volumes are not explicitly detailed in the quarterly data. - Explicit outlook: - Management commentary mentions confidence in tripling consolidated business over next three years through disciplined execution and operational excellence (Page 5). Q1 FY27 EBITDA: ₹8.5 crores, up 65% YoY from ₹5.2 crores in Q1 FY26 - Q1 FY27 EBITDA margin: 25.3%, improvement of 334 basis points YoY from 21.9% in Q1 FY26 - Q1 FY27 Profit After Tax (PAT): ₹5.1
What is Trident Lifeline Ltd share price analysis?
Trident Lifeline Ltd currently shows a neutral. The stock trades at a P/E of 23.9 with a market cap of ₹502 Cr. Investors should review the full earnings analysis for detailed insights.
Is Trident Lifeline Ltd planning capital expenditure?
Trident Lifeline Limited is investing in registrations, market access, sales infrastructure, and manufacturing to drive multi-year revenue growth and margin expansion (Page 26).
Keep Trident Lifeline Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.